Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine (opens in new tab)
Aclarion, Inc., leveraging biomarkers and proprietary AI algorithms through its Nociscan® announced it has established a second commercial agreement with Weill Cornell Medicine. The post Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine appeared first on Orthopedics This Week.
Read the original article